166 related articles for article (PubMed ID: 19259617)
1. Intravenous immune globulin usage for neurological and neuromuscular disorders: an academic centre, 4 years experience.
Sarti L; Falai T; Pinto F; Tendi E; Matà S
Neurol Sci; 2009 Jun; 30(3):213-8. PubMed ID: 19259617
[TBL] [Abstract][Full Text] [Related]
2. Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995-2000.
Pendergrast JM; Sher GD; Callum JL
Vox Sang; 2005 Oct; 89(3):150-60. PubMed ID: 16146507
[TBL] [Abstract][Full Text] [Related]
3. Use of intravenous immunoglobulin in an Asian paediatric population over a 10-year period.
Wu J; Lee AJ; Goh AE; Chia M; Ho C; Bugarin JL; Shek LP; Chan YH; Lee BW
J Paediatr Child Health; 2013 Aug; 49(8):629-34. PubMed ID: 23750995
[TBL] [Abstract][Full Text] [Related]
4. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
5. Long-term day-case treatment of peripheral neuromuscular disease with intravenous immunoglobulin: the practice of a regional day-case service in Preston, Lancashire.
Nixon J; McHugh C; Jones S
Clin Med (Lond); 2013 Aug; 13(4):358-61. PubMed ID: 23908504
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
Front Immunol; 2021; 12():740517. PubMed ID: 34603326
[TBL] [Abstract][Full Text] [Related]
7. Intravenous Immunoglobin Utilization Study in a Teaching Hospital.
Rezaie N; Shajareh E; Motamed MR; Ghanbari B; Pakdaman N; Farasatinasab M
Arch Iran Med; 2019 May; 22(5):232-235. PubMed ID: 31256594
[TBL] [Abstract][Full Text] [Related]
8. Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol.
Ruiz-Antorán B; Agustí Escasany A; Vallano Ferraz A; Danés Carreras I; Riba N; Mateu Escudero S; Costa J; Sánchez Santiago MB; Laredo L; Durán Quintana JA; Castillo JR; Abad-Santos F; Payares Herrera C; Sádaba Díaz de Rada B; Gómez Ontañón E
Eur J Clin Pharmacol; 2010 Jun; 66(6):633-41. PubMed ID: 20204337
[TBL] [Abstract][Full Text] [Related]
9. Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals.
Balch A; Wilkes J; Thorell E; Pavia A; Sherwin CMT; Enioutina EY
Int Immunopharmacol; 2019 Nov; 76():105868. PubMed ID: 31487613
[TBL] [Abstract][Full Text] [Related]
10. Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9-year retrospective study.
Shemer A; Kivity S; Shoenfeld Y
Transfusion; 2018 Feb; 58(2):430-438. PubMed ID: 29193136
[TBL] [Abstract][Full Text] [Related]
11. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
12. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.
Darabi K; Abdel-Wahab O; Dzik WH
Transfusion; 2006 May; 46(5):741-53. PubMed ID: 16686841
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group.
Constantine MM; Thomas W; Whitman L; Kahwash E; Dolan S; Smith S; Caudle CJ; Burton E; Anderson DR;
Transfusion; 2007 Nov; 47(11):2072-80. PubMed ID: 17958537
[TBL] [Abstract][Full Text] [Related]
14. Use of Polyclonal Intravenous Immunoglobulin at a Paediatric Referral Hospital in South Africa Between 2009 and 2012.
Raiman S; Knight SE; Eley B; Welzel TB
J Clin Immunol; 2015 Oct; 35(7):668-74. PubMed ID: 26369911
[TBL] [Abstract][Full Text] [Related]
15. Clinical applications of immunoglobulin in neuromuscular diseases: focus on inflammatory myopathies.
Souza PV; Pinto WB; Oliveira AS
Arq Neuropsiquiatr; 2014 Dec; 72(12):966-71. PubMed ID: 25465778
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.
Nosadini M; Mohammad SS; Suppiej A; Sartori S; Dale RC;
Dev Med Child Neurol; 2016 Nov; 58(11):1180-1192. PubMed ID: 27242065
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Immune Globulin Stewardship Program at a Tertiary Academic Medical Center.
Rocchio MA; Schurr JW; Hussey AP; Szumita PM
Ann Pharmacother; 2017 Feb; 51(2):135-139. PubMed ID: 27758967
[TBL] [Abstract][Full Text] [Related]
18. Immune globulin use at a multihospital medical center.
Gajewski LK; Bailey EM; Brown PD; Chandrasekar PH
Am J Hosp Pharm; 1994 Mar; 51(6):801-5. PubMed ID: 8010320
[TBL] [Abstract][Full Text] [Related]
19. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?
Elovaara I; Hietaharju A
Acta Neurol Scand; 2010 Nov; 122(5):309-15. PubMed ID: 20085560
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immune globulin use in Canada.
Hanna K; Poulin-Costello M; Preston M; Maresky N
Can J Clin Pharmacol; 2003; 10(1):11-6. PubMed ID: 12687032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
